Log in to search using one of your social media accounts:

 

Forecasting PARP Inhibitor Resistance in Breast Cancer Patients
In this video, Dr. Elizabeth Swisher reviews the use of PARP inhibitors in ovarian cancer, and the importance of understanding how resistance to these agents develops. (Source: CancerNetwork)
Source: CancerNetwork - April 23, 2018 Category: Cancer & Oncology Authors: Elizabeth Swisher, MD Tags: Conferences/AACR Street Team Breast Cancer News Source Type: news

Hemp shows potential for treating ovarian cancer
(Experimental Biology 2018) Results from some of the first studies to examine hemp's ability to fight cancer show that it might one day be useful as plant-based treatment for ovarian cancer. Hemp is part of the same cannabis family as marijuana but doesn't have any psychoactive properties or cause addiction. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 23, 2018 Category: Cancer & Oncology Source Type: news

Promising Personalized Ovarian Cancer Vaccine Induces Immune Responses
A personalized cancer vaccine was well tolerated and was capable of inducing antitumor T-cell immunity in patients with recurrent ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers SiteTerms/www.cannabissciencetech.com/News Ovarian Cancer Source Type: news

Earlier detection of ovarian cancer
(Source: ScienceNOW)
Source: ScienceNOW - April 19, 2018 Category: Science Authors: Benson, P. J. Tags: twis Source Type: news

Boston Scientific buys Harker School grad's med-tech business for $275M
Boston Scientific Corp. said Monday that it has bought nVision Medical Corp., a med-tech firm founded by a Harker School graduate that's developing a device to screen women for ovarian cancer. The Star Tribune of Minneapolis reported that Massachusetts-based Boston Scientific (NYSE: BSX) will pay $150 million upfront and another $125 million in later payments to acquire San Bruno-based nVision. RELATED: Read Boston Scientific's full announcement NVision had raised only about $17 mill ion in funding… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 17, 2018 Category: Biotechnology Authors: Mark Reilly Source Type: news

' Clear Role' for PARP Inhibitors in Advanced Ovarian Cancer'Clear Role' for PARP Inhibitors in Advanced Ovarian Cancer
Recent approval of rucaparib gives patients with ovarian cancer another new option for maintenance therapy.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Latest Mesothelioma Immunotherapy Combination Looks Promising
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
Source: Asbestos and Mesothelioma News - April 17, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Boston Scientific buys nVision Medical for $275 million
Boston Scientific Corp. said Monday that it has bough nVision Medical Corp., a California med-tech firm that's developing a device to screen women for ovarian cancer. The Star Tribune reports on the deal by Massachusetts-based Boston Scientific (NYSE: BSX), which will pay $150 million upfront and another $125 million in later payments to acquire nVision. RELATED: Read Boston Scientific's full announcement The company sees a near-term market potential of abou t $500 million per year for nVision's… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 17, 2018 Category: American Health Authors: Mark Reilly Source Type: news

Love Your Hair Color? You Have 100 Genes to Thank
The researchers who pinpointed the origins of hair hue said their findings could improve understanding of health conditions linked to pigmentation, including skin, testicular, prostate and ovarian cancers. (Source: WebMD Health)
Source: WebMD Health - April 16, 2018 Category: Consumer Health News Source Type: news

Boston Sci Continues M & amp;A Hot Streak with nVision Buy
Boston Scientific isn’t slowing down with its M&A activity. This time the Marlborough, MA-based company is acquiring nVision Medical, a private company focused on women's health. The transaction consists of an upfront cash payment of $150 million, and up to an additional $125 million in potential clinical and commercial milestones over four years.  nVision’s device collects cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. “nVision Medical developed the first and only device cleared by the FDA to collect cells from the fallopian tubes,” K...
Source: MDDI - April 16, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Boston Scientific acquires NVision Medical in $275m deal
Boston Scientific (NYSE:BSX) said today it inked a $275 million deal to acquire women’s health-focused NVision Medical, which produces an FDA-cleared device designed to collect cells from fallopian tubes as an early diagnosis of ovarian cancer. In the deal, Boston Scientific will pay $150 million up front with an additional $125 million in possible milestone payments over four years. The company said it expects the acquisition to be immaterial on an adjusted basis in 2018 and 2019, and accretive after. “We estimate the near-term market opportunity to be $500 million with the potential to grow to&...
Source: Mass Device - April 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Oncology Women's Health Boston Scientific NVision Source Type: news

COUNTERPOINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients
Though LHRH agonists may be the preferred method of ovarian function suppression, ovarian ablation is a viable option for select premenopausal breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - April 15, 2018 Category: Cancer & Oncology Authors: Ann H. Partridge, MD, MPH Philip D. Poorvu, MD Tags: Breast Cancer Oncology Journal Source Type: news

POINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients
Reversible ovarian function suppression using LHRH agonists is the preferred first treatment for most premenopausal breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - April 15, 2018 Category: Cancer & Oncology Authors: Gini F. Fleming, MD Padma Rajagopal, MD Tags: Breast Cancer Oncology Journal Source Type: news

Penn study finds relationship between PTEN loss, potential for immune response in BRCA 1/2-deficient ovarian cancer
(University of Pennsylvania School of Medicine) he protein known as phosphatase and tensin homolog (PTEN) is frequently mutated or affected by cancer as tumors develop. Now a new study from the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania shows PTEN may serve as a marker for whether a patient with BRCA 1-2 deficient ovarian cancer is likely to respond to checkpoint inhibitor therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2018 Category: Cancer & Oncology Source Type: news

Having chlamydia DOUBLES women's risk of developing ovarian cancer, study finds
(Natural News) Research reveals that chlamydia, the most common sexually transmitted disease (STD), can increase a woman’s risk of ovarian cancer by as much as 50 percent. The study’s results determined that women suffering from chronic chlamydia infections “had twice the risk of ovarian cancer compared to women with no evidence of ever having been infected.” According to... (Source: NaturalNews.com)
Source: NaturalNews.com - April 14, 2018 Category: Consumer Health News Source Type: news

Medical News Today: Personalized vaccine fights off cancer in clinical trial
A groundbreaking new pilot study designs personalized tumor vaccines for people with late-stage ovarian cancer. The results are promising. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 13, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Stop Screening for Early Ovarian Cancer, USPSTF Says Stop Screening for Early Ovarian Cancer, USPSTF Says
There is no evidence that screening actually improves outcomes in ovarian cancer, according to a USPSTF analysis of the best available data.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Personalized vaccine doubly effective at prolonging lives of women with advanced ovarian cancer
In a University of Pennsylvania study women who received personalized vaccines in combination with chemo had double the two-year survival rate of those treated with chemo alone. (Source: the Mail online | Health)
Source: the Mail online | Health - April 12, 2018 Category: Consumer Health News Source Type: news

A personalized vaccine helps patients fight back against ovarian cancer
In early research that extends the possibilities of immunotherapy to a killer feared by women, a personalized vaccine helped patients with ovarian cancer mount a stronger defense against their tumors and substantially improved their survival rate.The vaccine was tested in a preliminary clinical... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - April 12, 2018 Category: Science Authors: Melissa Healy Source Type: news

Talcum Powder Lawsuit: J & J, Imerys to Pay $80M in Punitive Damages
Johnson & Johnson and talc supplier Imerys SA must pay an additional $80 million in punitive damages to a man who said he developed mesothelioma after using asbestos-contaminated talcum powder, a New Jersey state court jury ruled Wednesday. The court has awarded $117 million in total damages in the case. Last week, a New Brunswick, New Jersey, jury ordered J&J and Imerys to pay $37 million in compensatory damages to plaintiff Stephen Lanzo III and his wife. It was the first trial loss for J&J over allegations that its talc-based products contain deadly asbestos. Last year, a Los Angeles Superior Court ruled in...
Source: Asbestos and Mesothelioma News - April 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA Approves Rucaparib for Recurrent Ovarian Cancer Maintenance Therapy
The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers SiteTerms/www.cannabissciencetech.com/News Ovarian Cancer Source Type: news

Ovarian cancer vaccine shows promising results in human study
Immunotherapy has gained ground against a stubborn opponent: ovarian cancer. A personalized cancer vaccine is safe and may lengthen the lives of ovarian cancer patients, a small clinical trial found. (Source: CNN.com - Health)
Source: CNN.com - Health - April 11, 2018 Category: Consumer Health News Source Type: news

Ovarian cancer vaccine shows promising results
Immunotherapy has gained ground against a stubborn opponent: ovarian cancer. A personalized cancer vaccine is safe and may lengthen the lives of ovarian cancer patients, a small clinical trial found. (Source: CNN.com - Health)
Source: CNN.com - Health - April 11, 2018 Category: Consumer Health News Source Type: news

Personalized tumor vaccine shows promise in pilot trial
(University of Pennsylvania School of Medicine) A new type of cancer vaccine has yielded promising results in an initial clinical trial. The personalized vaccine is made from patients' own immune cells, which are exposed to the contents of the patients' tumor cells, and injected into the patients to initiate a wider immune response. The trial, conducted in advanced ovarian cancer patients, showed that about half of the vaccinated patients had signs of anti-tumor T-cell responses. The study is published today in Science Translational Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 11, 2018 Category: International Medicine & Public Health Source Type: news

The Rivkin Center awards $1.185 million in ovarian cancer research grants
(GreenRubino) The Rivkin Center for Ovarian Cancer, a Seattle-based 501(c)(3), announced that it has awarded $1.185 million in ovarian cancer research grants for 2018. The amount funded was a 10 percent increase from the previous year. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 11, 2018 Category: International Medicine & Public Health Source Type: news

Ludwig researchers devise and test pioneering personalized ovarian cancer vaccine
(Ludwig Institute for Cancer Research) A Ludwig Cancer Research study has shown that an entirely new type of personalized cancer vaccine induces novel, potent and clinically effective immune responses in patients receiving a combination of standard therapies for recurrent, stage III and IV ovarian cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 11, 2018 Category: International Medicine & Public Health Source Type: news

Training the immune system to fight ovarian cancer
(American Association for the Advancement of Science) A personalized cancer vaccine safely and successfully boosted immune responses and increased survival rates in patients with ovarian cancer, according to results from a pilot clinical trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2018 Category: Cancer & Oncology Source Type: news

Losing weight can be a cancer warning and not a sign of good health
A review by Oxford University has found that weight loss is directly linked to cancer including bowel, ovarian and prostate. (Source: the Mail online | Health)
Source: the Mail online | Health - April 10, 2018 Category: Consumer Health News Source Type: news

FDA Approves Rucaparib as Maintenance Therapy for Ovarian Cancer FDA Approves Rucaparib as Maintenance Therapy for Ovarian Cancer
The new FDA action does not require biomarker testing prior to prescribing.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval
Clovis Oncology won the fast-tracked verdict it hoped for on Friday when the  U.S. Food and Drug Administration approved marketing the company's ovarian cancer drug rucaparib to treat a broader range of patients. The FDA approved the Boulder-based company (Nasdaq: CLVS) selling rucaparib as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tu be, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. The FDA completed its… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 6, 2018 Category: American Health Authors: Greg Avery Source Type: news

Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval
Clovis Oncology won the fast-tracked verdict it hoped for on Friday when the  U.S. Food and Drug Administration approved marketing the company's ovarian cancer drug rucaparib to an expanded range of patients. The FDA approved the Boulder-based company (Nasdaq: CLVS) selling rucaparib as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. That means more women with… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 6, 2018 Category: Biotechnology Authors: Greg Avery Source Type: news

J & J Loses Case Linking Mesothelioma to Asbestos in Talc
Johnson & Johnson suffered its first loss in an asbestos-related talcum powder lawsuit Thursday after a New Jersey jury ordered the company and its talc supplier to pay $37 million in damages. The jury awarded $30 million in compensatory damages to Stephen Lanzo III, who claims he developed mesothelioma after using Johnson & Johnson’s Shower to Shower and Baby Powder products from 1972 to 2003. His wife, Kendra, was awarded $7 million in damages. Johnson & Johnson was held 70 percent liable in the case, meaning they must pay $25.9 million. France-based talc supplier Imerys SA is liable for the remaining 3...
Source: Asbestos and Mesothelioma News - April 6, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

J & J Loses Talcum Powder Lawsuit
Johnson & Johnson suffered its first loss in an asbestos-related talcum powder lawsuit Thursday after a New Jersey jury ordered the company and its talc supplier to pay $37 million in damages. The jury awarded $30 million in compensatory damages to Stephen Lanzo III, who claims he developed mesothelioma after using Johnson & Johnson’s Shower to Shower and Baby Powder products from 1972 to 2003. His wife, Kendra, was awarded $7 million in damages. Johnson & Johnson was held 70 percent liable in the case, meaning they must pay $25.9 million. France-based talc supplier Imerys SA is liable for the remaining 3...
Source: Asbestos and Mesothelioma News - April 6, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
BOULDER, Colo.--(BUSINESS WIRE)--Apr. 6, 2018-- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.S. Food and Drug Administration (FDA) has approved Rubraca (rucaparib) tablets for the maintenance treatment of adult patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 6, 2018 Category: Drugs & Pharmacology Source Type: news

Colleen's Dream Foundation funds ovarian cancer clinical trial
(The Translational Genomics Research Institute) Colleen's Dream Foundation, a Scottsdale-based nonprofit dedicated to supporting ovarian cancer research, recently awarded Translational Genomics Research Institute (TGen) $450,000 to fund a clinical trial for a newly developed ovarian cancer drug treatment. TGen, based in Phoenix, alongside an international team of collaborators, discovered a mutation in a gene known as SMARCA4, which drives a specific type of extremely aggressive ovarian cancer known as Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 3, 2018 Category: Cancer & Oncology Source Type: news

The 7 Best Foods for Fighting Inflammation
The following story is excerpted from TIME’s special edition, 100 Most Healing Foods, which is available in stores, at the Meredith Shop and at Amazon. Inflammation is our body’s healthy response to fighting disease. But when it gets out of hand, inflammation can become chronic and lead to a whole host of health problems, from autoimmune diseases to cancer. Foods high in sugar and saturated fat are thought to contribute to inflammation, which is why some people who have inflammatory conditions and autoimmune disorders try out low-sugar diets. On the flip side, there are also foods to pile onto your plate that m...
Source: TIME: Health - April 2, 2018 Category: Consumer Health News Authors: Alexandra Sifferlin Tags: Uncategorized Diet/Nutrition healthytime Source Type: news

PARP-7 Amplification Mutations Linked to Prolonged Survival in Ovarian Cancer
A study presented at the SGO Annual Meeting found that PARP-7 amplification mutations are associated with prolonged survival among patients with platinum-sensitive ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 30, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: News Ovarian Cancer Conferences/SGO Source Type: news

Researchers Making Inroads Against Ovarian Cancer
(Source: Cancercompass News: Gynecological Cancer)
Source: Cancercompass News: Gynecological Cancer - March 30, 2018 Category: Cancer & Oncology Source Type: news

Mail-order cancer tests are WRONG 40% of the time, analysis claims
An analysis has revealed that almost half of the results from some at-home DNA tests for the 'Angelina Jolie gene' related to increased breast and ovarian cancer risk were false positives. (Source: the Mail online | Health)
Source: the Mail online | Health - March 29, 2018 Category: Consumer Health News Source Type: news

Researchers Making Inroads Against Ovarian Cancer
One study found that a new targeted "immunotherapy" to treat ovarian cancer that has come back looked promising in a small, early trial. (Source: WebMD Health)
Source: WebMD Health - March 29, 2018 Category: Consumer Health News Source Type: news

Researchers Making Progress Against Ovarian Cancer
One study found that a new targeted "immunotherapy" to treat ovarian cancer that has come back looked promising in a small, early trial. (Source: WebMD Health)
Source: WebMD Health - March 29, 2018 Category: Consumer Health News Source Type: news

Researchers Making Inroads Against Ovarian Cancer
THURSDAY, March 29, 2018 -- Ovarian cancer can be tough to beat, particularly if it returns after initial treatment, but new research offers a glimmer of hope. One study found that a new targeted " immunotherapy " to treat ovarian cancer that has come... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 29, 2018 Category: General Medicine Source Type: news

Researchers Making Inroads Against Ovarian Cancer
Title: Researchers Making Inroads Against Ovarian CancerCategory: Health NewsCreated: 3/29/2018 12:00:00 AMLast Editorial Review: 3/29/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - March 29, 2018 Category: Cancer & Oncology Source Type: news

Studies Seek Role for Anti-PD-1 Drugs in Gyn Cancers
(MedPage Today) -- Activity in resistant ovarian, mutated endometrial cancers (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 28, 2018 Category: Hematology Source Type: news

Mutant protein linked to ovarian cancer could be new treatment target
Researchers have found a mutant protein that is linked to ovarian cancer growth, prompting the possibility of new drugs to target this regulator. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 28, 2018 Category: Consumer Health News Source Type: news

Targeted Combo Active in Advanced Ovarian Cancer
(MedPage Today) -- Response rate as high as 72% with PARP plus PD-1/PD-L1 inhibition (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 28, 2018 Category: Hematology Source Type: news

Research uncovers a potential new strategy to fight ovarian cancer
(Baylor College of Medicine) Researchers discovered a potential novel way to regulate ovarian cancer growth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 28, 2018 Category: Cancer & Oncology Source Type: news

Trial Participation May Offset Disparities in Ovarian Cancer Care
A single-institution study of patients with advanced/recurrent EOCs found no overall survival differences for Caucasians and minorities who had participated in a clinical trial. (Source: CancerNetwork)
Source: CancerNetwork - March 27, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: News Ovarian Cancer Conferences/SGO Source Type: news

Repurposing inhibitors may provide new treatment approach for ovarian cancer
(The Wistar Institute) Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 27, 2018 Category: Cancer & Oncology Source Type: news